High-yield points
- LITT vs. open surgery:
- What LITT offers: a minimally invasive approach, a 1–3-day stay and fewer complications (18% vs. 30%).
- The cost: somewhat lower seizure freedom (54% vs. 68%), especially in children and extratemporal epilepsy .
- Failure isn't final: it doesn't preclude open surgery.
- MTLE:
- Engel I: about 50–60% (about 60% with MTS, and up to 90% in a small pediatric MTS series).
- Durability: 49% at about 4 years .
- Cognition: better naming and memory than open resection .
- Targeting: ablate the amygdala and anterior hippocampus.
- After failure: ATL rescues two-thirds .
- SLATE (prospective pivotal trial, adults): 56% Engel I at 12 months, 7.9% qualifying adverse events, and naming and verbal memory preserved .
- Hypothalamic hamartoma:
- LITT is first-line, with seizure freedom about 75% .
- Strategy: disconnect the attachment and stage large lesions .
- Risks: memory and endocrine effects.
- Callosotomy:
- LITT matches open surgery for drop attacks (about 50% drop-free).
- Hospital stay: 2 vs. 6 days.
- Downside: more re-operations.
- Keep it to 1–2 trajectories .
- Lesional:
- FCD II and TSC: results similar to resection .
- Cavernoma: 82% Engel I, with no hemorrhage .
- PVNH: 80% if unilateral .
- Use SEEG to define the target when the anatomy doesn't .
Landmark papers
- SLATE (Visualase pivotal trial; ClinicalTrials.gov results 2025): the first prospective multicenter trial of laser amygdalohippocampotomy for mesial temporal lobe epilepsy (adults). It gave 56% Engel I at 12 months with preserved naming and verbal memory .
MR-guided laser interstitial thermal therapy (LITT; also MRgLITT or stereotactic laser ablation, SLA) works through a small skull bolt:
- Ablation: an optical fiber destroys an epileptogenic target under real-time MR thermometry.
- Its appeal in children:
- no craniotomy;
- a 1–3-day stay;
- little pain;
- sparing of overlying cortex and white matter;
- and no barrier to later open surgery .
- The trade-off: somewhat lower seizure-freedom rates than open resection for many indications .
Overall evidence vs. open surgery
- Comparative meta-analysis, non-tumoral epilepsy (389 LITT vs. 557 open) :
- Complete seizure freedom: 53.7% vs. 68.1% (RR 0.81, P = .07). The difference reached significance when the resection was directed at the epileptogenic zone.
- Open surgery did better in the pediatric and extratemporal subgroups.
- Complications: 18.3% vs. 30.0% (significantly fewer with LITT).
- Hospital stay: 3.4 vs. 6.8 days.
- Reoperation: similar (13.1% vs. 13.4%).
- Children, 13 centers (268 patients) :
- Seizure freedom at 1 year: 44.4%.
- Predictors of seizure freedom:
- video-EEG concordance;
- lesion size;
- preoperative seizure frequency;
- number of antiseizure medications.
- Early pediatric lesional series (17 children, mostly FCD) :
- Engel I: 41%.
- Complications: in 4.
- Mean stay: 1.56 days.
Mesial temporal lobe epilepsy and SLATE
- Laser amygdalohippocampotomy (SLAH) :
- Engel I at 1 year: 53.4% overall.
- By MTS status: 60.5% with mesial temporal sclerosis vs. 33.3% without.
- Repeat ablation made 3 of 9 seizure-free.
- Verbal memory was better than in historical open-resection data.
- Naming and recognition are spared :
- Dominant-side open resection: 21 of 22 patients declined on naming.
- SLAH: no patient declined on naming or famous-face recognition.
- Targeting matters (multicenter, 234 patients) :
- Engel I: 58% at 1 and 2 years.
- Ablations that worked were anterior, medial and inferior. Prioritize the amygdala, then the hippocampal head, parahippocampal gyrus and rhinal cortices.
- Extending posteriorly gave diminishing returns.
- Prior focal-to-bilateral tonic–clonic seizures predicted failure.
- Durability (11 centers, 268 patients) :
- Engel I: 55.8% at 1 year, 52.5% at 2 years and 49.3% at last follow-up (median 47 months).
- Bilateral tonic–clonic seizures predicted recurrence.
- Rescue for failures:
- anterior temporal lobectomy, which made 66.7% seizure-free;
- repeat LITT, 50%.
- Prospective LAANTERN registry (145 patients, 14 under 22 years) :
- Engel I at 2 years: 58.4%.
- Pediatric outcomes were similar to adult outcomes.
- Adverse events: 16.5%, mostly mild.
- Recovery: a median stay of 1 day, and 96.6% went home.
- Children specifically (19 patients, aged 8–20) :
- Overall: Engel I in 73.5%.
- With MRI hippocampal sclerosis: 90% (9 of 10).
- MRI-normal: 55.5%.
- SLATE (Stereotactic Laser Ablation for Temporal Lobe Epilepsy), the Visualase pivotal trial :
- Design :
- Prospective, multicenter (US), single-arm trial.
- Primary endpoints: Engel I at 12 months, and device-, procedure- or anesthesia-related adverse events.
- Why single-arm: a randomized trial was judged not feasible because the device was already cleared and marketed.
- Population: adults only (aged 18–70; mean age 44) :
- 167 enrolled; 114 treated with laser ablation of the amygdala and hippocampus.
- 107 completed 12-month follow-up.
- Seizure outcome :
- Engel I at 12 months: 56.0% (95% CI 46.2–65.8). Retreated patients were counted as failures.
- Primary endpoint met: the lower confidence bound exceeded the prespecified 43%.
- Compared with historical medical therapy (8%): clearly better.
- Compared with historical open resection (64%): the lower confidence bound (46.2%) fell short of the 54% threshold implied by the prespecified 10% non-inferiority margin.
- Safety: qualifying adverse events in 7.9% (95% CI 3.7–14.5). These were moderate-to-severe, permanent device- or procedure-related events .
- Cognition: at 12 months, Boston Naming (−0.1 points) and Rey Auditory Verbal Learning (−0.9 points) scores were non-inferior to baseline .
- Quality of life: QOLIE-31 improved by a clinically significant amount in 38 of 93 patients and worsened in 1 .
- Takeaway:
- SLATE gives the first prospective, multicenter level of evidence for laser amygdalohippocampotomy: about 56% Engel I at 1 year, with preserved naming and memory.
- This matches the retrospective series above.
- It enrolled no children.
- Bottom line:
- Seizure control: LITT gives about 50–60% Engel I in MTLE, now confirmed prospectively in SLATE (56%) , versus higher rates with anterior temporal lobectomy.
- Cognition: LITT gives better naming and memory preservation, which is especially relevant for dominant-hemisphere surgery .
- Good candidates:
- unilateral MTS;
- concordant workup;
- no bilateral tonic–clonic seizures.
- Staging: offer ATL as a planned second step if needed .
Hypothalamic hamartoma
- LITT (with radiofrequency thermocoagulation) is now first-line :
- Individual-patient meta-analysis (517 patients) :
- Seizure freedom at last follow-up: LITT 74.5% and RF thermocoagulation 78.5%. These were the highest of any technique.
- Major complications: fewer than with open microsurgery.
- Stereotactic radiosurgery was safest (0% major complications), but less effective.
- Lower odds of seizure freedom: multiple seizure types and previous surgery.
- Series results:
- 71 patients :
- free of gelastic seizures at 1 year: 93%;
- more than one ablation needed: 23%;
- complications: one significant memory deficit, and one worsening of diabetes insipidus.
- 58 children :
- gelastic-free at last follow-up: 81%;
- secondary nongelastic epilepsy: 15 of 22 free of those seizures.
- Disconnection, not destruction :
- Residual hamartoma: 43% in seizure-free patients vs. 71% in those with continued seizures.
- Complete ablation isn't necessary. Target the attachment zone to disconnect the epileptogenic network.
- Large hamartomas often need staged ablations, which also limits risk to the hypothalamus, fornix and mammillary bodies.
- Risks to counsel:
- short-term memory loss (fornix and mammillothalamic tract);
- hypothalamic and endocrine effects (diabetes insipidus, hyperphagia/weight gain);
- the risk to the hypothalamus itself .
Corpus callosotomy
- Indication: palliation of drop attacks (atonic or tonic seizures), often in Lennox–Gastaut syndrome, as with open callosotomy.
- LITT vs. open callosotomy (individual-patient meta-analysis, 90 LITT vs. 858 open) :
- Similar outcomes:
- seizure freedom: 14.5% vs. 20.0%;
- drop-attack freedom: 51.3% vs. 45.1%;
- 50% or greater reduction: 52.6% vs. 55.2%.
- Hospital stay: shorter (2 vs. 6 days).
- Further epilepsy surgery: more often (24.4% vs. 10.1%).
- Complications: similar (31.3% vs. 22.9%). With 1–2 trajectories, 13.2%; with 3–5, 54.8%.
- Pooled LITT callosotomy (57 procedures) :
- Atonic seizures: complete freedom in 52.5%, and Engel I–II in 72.5%.
- Complications:
- fiber-related hemorrhage, 8.6%;
- inaccurate placement, 6.9%;
- transient hemiparesis or hemineglect and SMA syndrome, 5.2% each;
- disconnection syndrome, 3.4%.
- Completion callosotomy (ablating the residual splenium after a prior partial section) avoids a second interhemispheric craniotomy. In a series of 6, the 3 children had only Engel III–IV outcomes .
- Technical points:
- Use as few trajectories as possible .
- Confirm the disconnection on postoperative DWI.
- Remember the medial motor cortex and SMA near the entry path .
Lesional ablation
- FCD type II and tuberous sclerosis (meta-analysis, 87 LITT vs. 1,220 resection) :
- Combined seizure freedom: similar (0.72 vs. 0.71).
- FCD II alone: 0.74 vs. 0.85 (P = .065).
- TSC alone: 0.50 vs. 0.59.
- Complications: similar.
- Age (under vs. over 18) did not change outcome.
- Ideal FCD targets: small, deep bottom-of-sulcus FCD (often with a transmantle sign) and insulo-opercular lesions. Here open resection means traversing eloquent cortex.
- Tuberous sclerosis (40 children, median age 3.6) :
- Total seizures reduced by more than 50%: 80%.
- Free of the targeted seizure type: 58%.
- Developmental gains reported: 63%.
- Medications reduced: 40%.
- Planning: SEEG often identifies the epileptogenic tuber(s) first .
- Ablation volume / tuber volume ratio was higher with Engel I (1.28 vs. 0.84) in a small series .
- Cavernous malformation (19 patients) :
- Engel I: 82%.
- Hemorrhage: none caused by the ablation.
- Lesion involution: a median 83% volume reduction.
- Deficits: two, both predictable and neither permanently disabling.
- Technique: ablate the lesion plus the surrounding hemosiderin-stained cortex. Note that hemosiderin causes thermometry artifact.
- Periventricular nodular heterotopia (39 patients, SEEG-guided) :
- ILAE 1:
- 80% for unilateral PVNH alone;
- 63% with MTS or polymicrogyria;
- 50% for bilateral PVNH.
- What predicted outcome: the percentage of the seizure-onset zone ablated.
- Epilepsy-associated tumors: see Supratentorial LGG. Biopsy first, and note that seizure-outcome data in children are limited.
Related topics
- Temporal Lobe Epilepsy Surgery: LITT versus ATL and SAH.
- Hypothalamic Hamartoma: the best-established LITT indication.
- Corpus Callosotomy: open versus laser callosotomy.
- Supratentorial LGG: epilepsy-associated tumors.
- Epilepsy Surgery Overview: surgical context.
- Subependymal Giant Cell Astrocytoma (SEGA): Management: LITT for SEGA.
- Cerebral Cavernous Malformations in Children: laser ablation of cavernomas.
- Corpus Callosotomy: Procedure: step-by-step procedure.
References
- Gross RE, Stern MA, Willie JT, et al. Stereotactic laser amygdalohippocampotomy for mesial temporal lobe epilepsy. Ann Neurol 2018;83(3):575–587. doi:10.1002/ana.25180. PMID 29420840. verified
- Arocho-Quinones EV, Lew SM, Handler MH, et al. Magnetic resonance-guided stereotactic laser ablation therapy for the treatment of pediatric brain tumors: a multiinstitutional retrospective study. J Neurosurg Pediatr 2020;26(1):13–21. doi:10.3171/2020.1.PEDS19496. PMID 32217793. verified
- Willie JT, Malcolm JG, Stern MA, et al. Safety and effectiveness of stereotactic laser ablation for epileptogenic cerebral cavernous malformations. Epilepsia 2019;60(2):220–232. doi:10.1111/epi.14634. PMID 30653657. verified
- Maroufi SF, Fallahi MS, Amirkhani N, et al. Laser interstitial thermal therapy versus open resective surgery for nontumoral epilepsy: systematic review and meta-analysis of comparative studies. J Neurosurg 2026;144(4):787–798. doi:10.3171/2025.8.JNS25496. PMID 41576371. verified
- Yossofzai O, Stone SSD, Madsen JR, et al. Machine learning models for predicting seizure outcome after MR-guided laser interstitial thermal therapy in children. J Neurosurg Pediatr 2023;32(6):739–749. doi:10.3171/2023.8.PEDS23240. PMID 37856414. verified
- Lewis EC, Weil AG, Duchowny M, et al. MR-guided laser interstitial thermal therapy for pediatric drug-resistant lesional epilepsy. Epilepsia 2015;56(10):1590–1598. doi:10.1111/epi.13106. PMID 26249524. verified
- Drane DL, Loring DW, Voets NL, et al. Better object recognition and naming outcome with MRI-guided stereotactic laser amygdalohippocampotomy for temporal lobe epilepsy. Epilepsia 2015;56(1):101–113. doi:10.1111/epi.12860. PMID 25489630. verified
- Wu C, Jermakowicz WJ, Chakravorti S, et al. Effects of surgical targeting in laser interstitial thermal therapy for mesial temporal lobe epilepsy: a multicenter study of 234 patients. Epilepsia 2019;60(6):1171–1183. doi:10.1111/epi.15565. PMID 31112302. verified
- Youngerman BE, Banu MA, Khan F, et al. Long-term outcomes of mesial temporal laser interstitial thermal therapy for drug-resistant epilepsy and subsequent surgery for seizure recurrence: a multi-centre cohort study. J Neurol Neurosurg Psychiatry 2023;94(11):879–886. doi:10.1136/jnnp-2022-330979. PMID 37336643. verified
- Landazuri P, Cheng JJ, Leuthardt E, et al. Interstitial thermal therapy in mesial temporal lobe epilepsy. JAMA Neurol 2025;82(9):915–924. doi:10.1001/jamaneurol.2025.1897. PMID 40622685. verified
- Trivedi AM, Montenegro MA, Gonda D, et al. Laser interstitial thermal therapy for the treatment of mesial temporal lobe epilepsy in children. J Child Neurol 2025;40(5):342–347. doi:10.1177/08830738241312262. PMID 39887192. verified
- Sperling MR, Gross RE, Alvarez GE, et al. Stereotactic laser ablation for mesial temporal lobe epilepsy: a prospective, multicenter, single-arm study. Epilepsia 2020;61(6):1183–1189. doi:10.1111/epi.16529. PMID 32412094. verified
- Medtronic. Stereotactic Laser Ablation for Temporal Lobe Epilepsy (SLATE). ClinicalTrials.gov identifier NCT02844465. Results first posted 2025-01-17. (verified on ClinicalTrials.gov)
- Wu C, Busch RM, Drane DL, et al. Comparative review of seizure and cognitive outcomes in resective, ablative, and neuromodulatory temporal lobe epilepsy surgery. Epilepsy Curr 2025;25(5):290–296. doi:10.1177/15357597251318564. PMID 40028188. verified
- Niazi F, Goel K, Chen JS, et al. Outcome of surgery for hypothalamic hamartoma-related epilepsy: a systematic review and individual participant data meta-analysis. Neurology 2024;103(12):e210060. doi:10.1212/WNL.0000000000210060. PMID 39642321. verified
- Curry DJ, Raskin J, Ali I, Wilfong AA. MR-guided laser ablation for the treatment of hypothalamic hamartomas. Epilepsy Res 2018;142:131–134. doi:10.1016/j.eplepsyres.2018.03.013. PMID 29631919. verified
- Gadgil N, Lam S, Pan IW, et al. Staged magnetic resonance-guided laser interstitial thermal therapy for hypothalamic hamartoma: analysis of ablation volumes and morphological considerations. Neurosurgery 2020;86(6):808–816. doi:10.1093/neuros/nyz378. PMID 31990344. verified
- Merenzon MA, O'Malley G, Terry F, et al. Stereotactic laser ablation vs open corpus callosotomy: a systematic review and meta-analysis of individual patient data. Oper Neurosurg 2026;30(5):641–652. doi:10.1227/ons.0000000000001709. PMID 40719433. verified
- Awad AJ, Kaiser KN. Laser ablation for corpus callosotomy: systematic review and pooled analysis. Seizure 2022;96:137–141. doi:10.1016/j.seizure.2022.02.002. PMID 35245877. verified
- Huang Y, Yecies D, Bruckert L, et al. Stereotactic laser ablation for completion corpus callosotomy. J Neurosurg Pediatr 2019;24(4):433–441. doi:10.3171/2019.5.PEDS19117. PMID 31374542. verified
- Wang Y, Tai Y, Liu T, et al. Efficacy and safety of MR guided-laser interstitial thermal therapy versus resective surgery for MRI-positive focal cortical dysplasia type II and tuberous sclerosis complex: a systematic review and meta-analysis. Seizure 2026;142:121–130. doi:10.1016/j.seizure.2026.08.021. PMID 42679657. verified
- Ortman C, Coorg R, Ali I, et al. Clinical outcomes following stereotactic MRI-guided laser ablation in children with tuberous sclerosis complex and intractable epilepsy. Epilepsia 2026;67(3):1169–1180. doi:10.1111/epi.70036. PMID 41367165. verified
- Stellon MA, Cobourn K, Whitehead MT, et al. "Laser and the tuber": thermal dynamic and volumetric factors influencing seizure outcomes in pediatric subjects with tuberous sclerosis undergoing stereoencephalography-directed laser ablation of tubers. Childs Nerv Syst 2019;35(8):1333–1340. doi:10.1007/s00381-019-04255-4. PMID 31209639. verified
- McCormack RM, Chandran AS, Lhatoo SD, et al. Laser ablation of periventricular nodular heterotopia for medically refractory epilepsy. Ann Neurol 2024;96(6):1174–1184. doi:10.1002/ana.27059. PMID 39297387. verified
Verification (2026-11-13): each reference's authors, title, journal, volume, pages, DOI and PMID were checked on PubMed. Numbers were checked against the PubMed abstracts.
SLATE (2026-11-17):
- The outcome numbers come from the sponsor's results posted on ClinicalTrials.gov (NCT02844465): enrollment, eligibility ages, 12-month Engel I with its 95% CI, the qualifying adverse event rate, Boston Naming and RAVLT change, and the QOLIE-31 categories. Each was checked against the registry record.
- PubMed and Europe PMC searches on 2026-11-17 found no peer-reviewed SLATE outcome article, only the 2020 design paper (reference 12). Replace reference 13 with the journal article once it is indexed.
- The comparison with the 54% open-resection threshold is our arithmetic from the registry's prespecified hypothesis (64% − 10%); the registry reports no p-value for it.
Caveats:
- The following are standard teaching, not drawn from the cited abstracts:
- the occipital trajectory;
- bottom-of-sulcus/insular FCD as ideal targets;
- the hamartoma risk list beyond memory and diabetes insipidus;
- DWI confirmation of callosotomy.
- Most MTLE data are adult or mixed. Most other series are small and retrospective.
- The figure is an original schematic.